A retrospective analysis assessing the efficacy and safety of Camrelizumab combined with albumin paclitaxel and cisplatin as neoadjuvant therapy for pts with locally advanced esophageal squamous cell carcinoma (ESCC)
Latest Information Update: 19 Jul 2021
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 19 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology